Concepedia

Christine Gennigens

CG

19

Publications

1K

Citations

15

H-Index

2000

Active since

Affiliations

Centre Hospitalier Universitaire de Liège(Current)

University of Liège

KU Leuven

Genmab (United States)

Creighton University

Christine Gennigens is an author at Centre Hospitalier Universitaire de Liège specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2000–2024

19

Publications

19

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 367 citations

, , +8

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

David S. Hong, Nicole Concin, Ignace Vergote et al. · Clinical Cancer Research · 2019 · 122 citations · Full text

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 116 citations · Full text

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E. O’Cearbhaill et al. · Journal of Clinical Oncology · 2023 · 71 citations · Full text

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Ignace Vergote, Agustin A. García, John P. Micha et al. · Journal of Clinical Oncology · 2013 · 52 citations · Full text

Rows per page

1–5 of 19